EPO Knocks Down Trio of Geron Patent Claims

Law360, New York (June 14, 2006, 12:00 AM EDT) -- In another blow to Geron Corp., the European Patent Office has ruled in favor of Danish pharmaceutical giant Pharmexa A/S and invalidated three claims of the U.S. biotechnology company’s European patent related to telomerase-targeted cancer vaccines.

On Wednesday, Pharmexa announced that the EPO had rejected a trio of Geron’s patent claims involving peptide vaccines against telomerase, an enzyme that adds specific DNA sequence repeats to the ends of DNA strands.

"It was a clear decision, solidly based on the arguments Pharmexa has presented,” said Jakob Schmidt,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.